What is he best known for?
The fields of study he is best known for:
- Gene
- Genetics
- Internal medicine
His scientific interests lie mostly in Genetics, MHC class I, Major histocompatibility complex, Gene and Human leukocyte antigen.
MHC class I is a subfield of CD8 that Seiamak Bahram investigates.
MHC Class I Gene is closely connected to ULBP2 in his research, which is encompassed under the umbrella topic of CD8.
His Major histocompatibility complex research is within the category of Immunology.
His Immunology research is multidisciplinary, incorporating elements of Receptor and Gut Epithelium.
Seiamak Bahram focuses mostly in the field of Human leukocyte antigen, narrowing it down to matters related to Immune system and, in some cases, HLA-DR Antigen.
His most cited work include:
- Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. (925 citations)
- Complete sequence and gene map of a human major histocompatibility complex (863 citations)
- Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1 (710 citations)
What are the main themes of his work throughout his whole career to date?
Seiamak Bahram mainly investigates Genetics, Immunology, Gene, Major histocompatibility complex and MHC class I.
As part of one scientific family, Seiamak Bahram deals mainly with the area of Immunology, narrowing it down to issues related to the Disease, and often Genome-wide association study.
He interconnects Molecular biology and Receptor in the investigation of issues within Gene.
His studies deal with areas such as Acquired immune system, Innate immune system, Sequence analysis and Gene family as well as Major histocompatibility complex.
His research integrates issues of Nucleic acid sequence and Peptide sequence in his study of MHC class I.
Seiamak Bahram has researched CD8 in several fields, including NKG2D and ULBP2.
He most often published in these fields:
- Genetics (38.04%)
- Immunology (30.67%)
- Gene (22.09%)
What were the highlights of his more recent work (between 2017-2021)?
- Immunology (30.67%)
- Cancer research (11.66%)
- Allele (15.34%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Immunology, Cancer research, Allele, Inflammation and Immune system.
The various areas that he examines in his Immunology study include Signal transduction, Disease and Knockout mouse.
He is exploring Allele as part of his Genetics and Gene and Allele studies.
Seiamak Bahram performs multidisciplinary study in Genetics and Dominant-Negative Mutation in his work.
His Gene study combines topics in areas such as Molecular biology, Hematopoietic stem cell transplantation and T cell.
His research investigates the link between Receptor and topics such as Single-nucleotide polymorphism that cross with problems in Human leukocyte antigen.
Between 2017 and 2021, his most popular works were:
- HLA*LA-HLA typing from linearly projected graph alignments. (21 citations)
- ZMIZ1 Variants Cause a Syndromic Neurodevelopmental Disorder (15 citations)
- Update on Fc-Mediated Antibody Functions Against HIV-1 Beyond Neutralization. (14 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Internal medicine
- Genetics
Seiamak Bahram mostly deals with Immunology, Allele, Human leukocyte antigen, Computational biology and Immune system.
His Immunology research incorporates elements of Knockout mouse and microRNA.
A significant part of his Allele research incorporates Genetics and Gene studies.
In his works, Seiamak Bahram conducts interdisciplinary research on Genetics and Androgen receptor.
His Major histocompatibility complex, Haplotype and Allele frequency study in the realm of Gene connects with subjects such as Mica.
His studies in Human leukocyte antigen integrate themes in fields like Genome, Nanopore sequencing and Pacific biosciences.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
